Pfizer terminated phase 3 development on two investigational compounds today after halting trials on axitinib, a phase 3 pancreatic cancer treatment, in January.
Monthly Prescribing Reference (MPR) has relaunched its website with a number of enhancements to functionality and design, as well as a new, easier-to-remember URL, www.eMPR.com.
Merck is betting on Democratic plans to speed development of generic biologics, making a play for the market with a new unit tasked with designing the products and promising, in the words of president and CEO Dick Clark, a “new Merck built for the new era that our industry has entered.”
Pfizer announced that the number of compounds it has in Phase 3 development has grown from 16 to 25 over the past six months, including eight cancer treatments.
Thomson Reuters names five most promising Q1 drugs
Seven potential blockbusters could emerge in 2008, according to IMS Health.
Product news
March 18, 2008
4:13 pm
Hawthorn Pharmaceuticals announced the FDA approval of the company’s Granisol (granisetron HCl) oral solution. Granisol is an oral solution for the prevention of nausea and vomiting associated with cancer therapy.